Insulet (PODD) Cash & Equivalents (2010 - 2026)

Insulet's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $480.4 million for Q1 2026.

• Quarterly Cash & Equivalents fell 62.56% year-over-year to $480.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $480.4 million (down 62.56% YoY) and the FY2025 annual result came in at $716.1 million, down 24.89% from the prior year.
• Cash & Equivalents was $480.4 million for Q1 2026 at Insulet, down from $716.1 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $1.3 billion in Q1 2025 and bottomed at $480.4 million in Q1 2026.
• A 5-year average of $780.7 million and a median of $716.1 million in 2025 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2025 — Cash & Equivalents surged 70.81% — and 2026, when it plunged 62.56%.
• Insulet's Cash & Equivalents stood at $674.7 million in 2022, then advanced by 4.37% to $704.2 million in 2023, then soared by 35.39% to $953.4 million in 2024, then declined by 24.89% to $716.1 million in 2025, then sank by 32.91% to $480.4 million in 2026.
• Business Quant data shows PODD's Cash & Equivalents at $480.4 million in Q1 2026, $716.1 million in Q4 2025, and $757.4 million in Q3 2025.